Comments_老虎社区_美港股上老虎

2022-01-30

Comments

2 Dirt-Cheap Value Stocks to Buy Now<blockquote>现在值得购买的2只非常便宜的价值股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":633008589,"tweetId":"633008589","gmtCreate":1643517234419,"gmtModify":1643517234686,"author":{"id":3582712430239719,"idStr":"3582712430239719","authorId":3582712430239719,"authorIdStr":"3582712430239719","name":"S071","avatar":"https://static.tigerbbs.com/1f21cc4747e7e36aaf24e423fd9d808b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Comments</body></html>","htmlText":"<html><head></head><body>Comments</body></html>","text":"Comments","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/633008589","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://www.laohu8.com/m/news/1191140677?lang=zh_CN&edition=full","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now<blockquote>现在值得购买的2只非常便宜的价值股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.<blockquote><html><head></head><body>总体而言，自上次重大金融危机以来，成长型股票的表现大幅优于价值型股票。处于历史低位的联邦基金利率（银行相互借贷的利率），加上美国政府大规模的财政刺激，是这场史无前例的长达14年的成长型股票牛市背后的主要驱动力。</body></html></blockquote>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.<blockquote>但随着美联储准备在今年推出一系列加息，在可预见的未来，价值股的表现可能会跑赢成长股。事实上，自2021年第四季度初以来，就总资本回报率而言，价值股已经开始击败成长股。</blockquote>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\">Takeda Pharmaceutical</a> and <a href=\"https://laohu8.com/S/VTRS\">Viatris</a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.<blockquote>考虑到这种强大的趋势逆转，投资者可能希望在2022年的头几周买入优质价值股。哪些价值投资是目前最值得购买的？派息医药股<a href=\"https://laohu8.com/S/TAK\">武田制药</a>和<a href=\"https://laohu8.com/S/VTRS\">维亚特里斯</a>目前两者的交易估值都非常便宜。这就是为什么投资者可能希望尽快将这两家制药商添加到他们的投资组合中。</blockquote><a href=\"https://laohu8.com/S/TAK\">Takeda Pharmaceutical</a>: An incredibly cheap high-yield dividend stock<blockquote><a href=\"https://laohu8.com/S/TAK\">武田制药</a>：一只极其便宜的高收益股息股票</blockquote>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.<blockquote>日本制药巨头武田是在长达14年的牛市中为数不多的下跌的主要制药商之一。在此期间，各种临床挫折、即将到期的专利、因收购罕见病专家Shire而导致的高杠杆资产负债表以及缺乏特许经营级药物都对其股价造成了压力。事实上，仅在过去三年里，武田的股价就下跌了近三分之一。然而，由于三个关键原因，该公司的股价现在似乎已经准备好出现重大逆转。</blockquote>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.<blockquote>首先，武田的Wave 1临床管线最近已经开始产生一些真正高价值的商业产品。例如，去年年底，该公司的移植后巨细胞病毒感染药物Livtencity和利基肺癌药物Exkivity获得了美国监管机构的两项重要批准。武田认为，这两种药物将有助于在2030财年之前推动可观的营收增长，并使其正在进行的去杠杆化进程保持在正轨上。</blockquote>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.<blockquote>其次，武田的股票目前交易价格是2022财年预计销售额的1.5倍。这无疑是目前主要药品制造领域中较低的市销率之一。实际上，武田是一只真正的价值股票。在当前以价值为导向的市场中，这应该有利于制药商的股价。</blockquote>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.<blockquote>第三，武田目前支付的年化股息收益率高达5.6%。该公司出色的收益率也资金充足，其派息率相当低（59.4%）就证明了这一点。</blockquote>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.<blockquote>总而言之，随着投资者转向纯价值股而远离风险较高的成长型股票，武田的股票应该会大放异彩。</blockquote><a href=\"https://laohu8.com/S/VTRS\">Viatris</a>: Stability and a top dividend yield<blockquote><a href=\"https://laohu8.com/S/VTRS\">维亚特里斯</a>：稳定性和最高股息收益率</blockquote>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.<blockquote>Viatris是一家仿制药和生物仿制药公司。自成立一年多以来，该公司股价已下跌超过10.4%。由于其负债累累的资产负债表、缺乏明确的增长产品以及相当温和的长期前景，Viatris的股票迄今为止未能让投资者兴奋。毕竟，该公司预计要到2024年才能实现可持续的营收增长。</blockquote>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.<blockquote>然而，尽管存在这些不利因素，Viatris股票应该会吸引注重价值的投资者。总而言之，Viatris的股票是目前派息制药股中绝对最便宜的股票之一。该制药商的股票目前的交易价格不到前瞻性销售额的一倍，这凸显了这一点。更重要的是，Viatris目前为股东提供的年化收益率（相对于同行）为3.29%，高于平均水平。</blockquote>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.<blockquote>因此，虽然Viatris股票不会很快让股东致富，但由于其廉价的估值和有吸引力的股息收益率，这只制药股票确实被视为一种高度安全的投资工具。Viatris一流的安全边际应该会被证明是这个规避风险的市场中的一个制胜特征。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now<blockquote>现在值得购买的2只非常便宜的价值股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now<blockquote>现在值得购买的2只非常便宜的价值股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2022-01-30 10:21\n\n</h4>\n</header>\n<article>\n<html><head></head><body>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.<blockquote><html><head></head><body>总体而言，自上次重大金融危机以来，成长型股票的表现大幅优于价值型股票。处于历史低位的联邦基金利率（银行相互借贷的利率），加上美国政府大规模的财政刺激，是这场史无前例的长达14年的成长型股票牛市背后的主要驱动力。</body></html></blockquote>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.<blockquote>但随着美联储准备在今年推出一系列加息，在可预见的未来，价值股的表现可能会跑赢成长股。事实上，自2021年第四季度初以来，就总资本回报率而言，价值股已经开始击败成长股。</blockquote>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\">Takeda Pharmaceutical</a> and <a href=\"https://laohu8.com/S/VTRS\">Viatris</a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.<blockquote>考虑到这种强大的趋势逆转，投资者可能希望在2022年的头几周买入优质价值股。哪些价值投资是目前最值得购买的？派息医药股<a href=\"https://laohu8.com/S/TAK\">武田制药</a>和<a href=\"https://laohu8.com/S/VTRS\">维亚特里斯</a>目前两者的交易估值都非常便宜。这就是为什么投资者可能希望尽快将这两家制药商添加到他们的投资组合中。</blockquote><a href=\"https://laohu8.com/S/TAK\">Takeda Pharmaceutical</a>: An incredibly cheap high-yield dividend stock<blockquote><a href=\"https://laohu8.com/S/TAK\">武田制药</a>：一只极其便宜的高收益股息股票</blockquote>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.<blockquote>日本制药巨头武田是在长达14年的牛市中为数不多的下跌的主要制药商之一。在此期间，各种临床挫折、即将到期的专利、因收购罕见病专家Shire而导致的高杠杆资产负债表以及缺乏特许经营级药物都对其股价造成了压力。事实上，仅在过去三年里，武田的股价就下跌了近三分之一。然而，由于三个关键原因，该公司的股价现在似乎已经准备好出现重大逆转。</blockquote>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.<blockquote>首先，武田的Wave 1临床管线最近已经开始产生一些真正高价值的商业产品。例如，去年年底，该公司的移植后巨细胞病毒感染药物Livtencity和利基肺癌药物Exkivity获得了美国监管机构的两项重要批准。武田认为，这两种药物将有助于在2030财年之前推动可观的营收增长，并使其正在进行的去杠杆化进程保持在正轨上。</blockquote>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.<blockquote>其次，武田的股票目前交易价格是2022财年预计销售额的1.5倍。这无疑是目前主要药品制造领域中较低的市销率之一。实际上，武田是一只真正的价值股票。在当前以价值为导向的市场中，这应该有利于制药商的股价。</blockquote>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.<blockquote>第三，武田目前支付的年化股息收益率高达5.6%。该公司出色的收益率也资金充足，其派息率相当低（59.4%）就证明了这一点。</blockquote>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.<blockquote>总而言之，随着投资者转向纯价值股而远离风险较高的成长型股票，武田的股票应该会大放异彩。</blockquote><a href=\"https://laohu8.com/S/VTRS\">Viatris</a>: Stability and a top dividend yield<blockquote><a href=\"https://laohu8.com/S/VTRS\">维亚特里斯</a>：稳定性和最高股息收益率</blockquote>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.<blockquote>Viatris是一家仿制药和生物仿制药公司。自成立一年多以来，该公司股价已下跌超过10.4%。由于其负债累累的资产负债表、缺乏明确的增长产品以及相当温和的长期前景，Viatris的股票迄今为止未能让投资者兴奋。毕竟，该公司预计要到2024年才能实现可持续的营收增长。</blockquote>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.<blockquote>然而，尽管存在这些不利因素，Viatris股票应该会吸引注重价值的投资者。总而言之，Viatris的股票是目前派息制药股中绝对最便宜的股票之一。该制药商的股票目前的交易价格不到前瞻性销售额的一倍，这凸显了这一点。更重要的是，Viatris目前为股东提供的年化收益率（相对于同行）为3.29%，高于平均水平。</blockquote>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.<blockquote>因此，虽然Viatris股票不会很快让股东致富，但由于其廉价的估值和有吸引力的股息收益率，这只制药股票确实被视为一种高度安全的投资工具。Viatris一流的安全边际应该会被证明是这个规避风险的市场中的一个制胜特征。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TAK":"武田制药","VTRS":"Viatris Inc."},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1,"symbols_score_info":{"VTRS":0.9,"TAK":0.9}},"isVote":1,"tweetType":1,"viewCount":2661,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/633008589"}